A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. Issue 11 (17th November 2016)
- Record Type:
- Journal Article
- Title:
- A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. Issue 11 (17th November 2016)
- Main Title:
- A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection
- Authors:
- Parameswarappa, Sharavathi Guddehalli
Reppe, Katrin
Geissner, Andreas
Ménová, Petra
Govindan, Subramanian
Calow, Adam D.J.
Wahlbrink, Annette
Weishaupt, Markus W.
Monnanda, Bopanna Ponnappa
Bell, Roland Lawrence
Pirofski, Liise-Anne
Suttorp, Norbert
Sander, Leif Erik
Witzenrath, Martin
Pereira, Claney Lebev
Anish, Chakkumkal
Seeberger, Peter H. - Abstract:
- Summary: The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity. Graphical Abstract: Highlights: Glycan arrays reveal epitopes of two monoclonal antibodies to S. pneumoniae 3 CPS CRM197 conjugates of one identified tetrasaccharide antigen are immunogenic in mice Vaccination with the glycoconjugates protects mice from pneumococcal pneumonia Abstract : Parameswarappa et al. describe a synthetic immunogenicSummary: The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity. Graphical Abstract: Highlights: Glycan arrays reveal epitopes of two monoclonal antibodies to S. pneumoniae 3 CPS CRM197 conjugates of one identified tetrasaccharide antigen are immunogenic in mice Vaccination with the glycoconjugates protects mice from pneumococcal pneumonia Abstract : Parameswarappa et al. describe a synthetic immunogenic tetrasaccharide hapten of the capsular polysaccharide of Streptococcus pneumoniae serotype 3. Glycoconjugates of this antigen are able to protect mice from pneumococcal pneumonia in a lethal transnasal challenge model. … (more)
- Is Part Of:
- Cell chemical biology. Volume 23:Issue 11(2016)
- Journal:
- Cell chemical biology
- Issue:
- Volume 23:Issue 11(2016)
- Issue Display:
- Volume 23, Issue 11 (2016)
- Year:
- 2016
- Volume:
- 23
- Issue:
- 11
- Issue Sort Value:
- 2016-0023-0011-0000
- Page Start:
- 1407
- Page End:
- 1416
- Publication Date:
- 2016-11-17
- Subjects:
- Streptococcus pneumoniae -- Synthetic glycans -- Glycan arrays -- Glycoconjugate vaccines -- Epitope mapping -- Opsonophagocytosis
Biochemistry -- Periodicals
572.05 - Journal URLs:
- http://www.cell.com/cell-chemical-biology/home ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.chembiol.2016.09.016 ↗
- Languages:
- English
- ISSNs:
- 2451-9456
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3097.733000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 1968.xml